Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of SAR445399, a drug administered by injection, in adults with moderate to severe hidradenitis suppurativa. This multinational, randomized, double-blind, placebo-controlled Phase 2 study aims to compare two different doses of SAR445399 with a placebo to find the best dose for treating this condition. Participants will be randomly assigned to receive one of two SAR445399 dose regimens or a matching placebo. The treatment period lasts 32 weeks, including a 16-week initial double-blind phase followed by a 16-week treatment-blinded extension period. The total study duration for each participant is up to 46 weeks, with a total of 16 study visits scheduled throughout this time. During the study, participants will be monitored through various assessments including clinical response measures such as Hidradenitis Suppurativa Clinical Response HiSCR levels, severity scoring, skin pain ratings, quality of life questionnaires, laboratory tests, vital signs, and electrocardiograms. Researchers will also track drug concentrations and immune responses. Safety will be closely monitored throughout the study and extension period to evaluate any adverse events or significant changes in health.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating ABS-201, a new investigational drug, in healthy adult men and women and in adults with androgenetic alopecia male- and female-pattern hair loss. The study aims to assess the safety, tolerability, how the body processes ABS-201, and its effects on related biological markers. This first-in-human trial includes participants both with and without androgenetic alopecia to understand the medications impact, including hair growth effects in those with the condition. The study has two parts first, a single ascending dose SAD phase where participants receive one intravenous dose of ABS-201 or placebo. Then, a multiple ascending dose MAD phase involves several subcutaneous doses of ABS-201 or placebo, including among men with androgenetic alopecia. The MAD phase also evaluates the drugs effect on hair growth. Doses vary in amount and are given according to a randomized and double-blind design. Participants will visit the study clinic for scheduled checkups and tests over approximately 12 months in the SAD phase and about 18 months in the MAD phase. Researchers will monitor for side effects, measure pharmacokinetics and pharmacodynamics, check for immune responses, and assess hair count and hair width in the MAD phase. Safety monitoring continues throughout, with comparisons made between ABS-201 and placebo groups to understand the medications effects fully.